Phase III Randomized, Placebo-Controlled Clinical Trial of Donepezil for Treatment of Cognitive Impairment in Breast Cancer Survivors After Adjuvant Chemotherapy (WF-97116)

CONCLUSION: BCS 1-5 years after completing chemotherapy with documented memory problems, randomly assigned to 24 weeks of 5-10 mg of donepezil once daily, did not perform differently at the end of treatment on tests of memory, other cognitive functions, or subjective functioning than those randomly assigned to placebo.PMID:38709986 | DOI:10.1200/JCO.23.01100

Source: Clinical Genitourinary Cancer - May 6, 2024 Category: Cancer & Oncology Authors: Stephen R Rapp Emily V Dressler W Mark Brown James L Wade Nguyet Le-Lindqwister David King Kendrith M Rowland Kathryn E Weaver Heidi D Klepin Edward G Shaw Glenn J Lesser Source Type: research